Alector, Inc. (ALEC)
NASDAQ$1.38
Market Cap
$136.74M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
438 of 924
Rank in Industry
258 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALEC Insider Trading Activity
ALEC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,266,609 | 19 | 100 |
Related Transactions
| Yaffe Kristine | director | 0 | $0 | 1 | $25,309 | $-25,309 |
| Hammond Paula | director | 0 | $0 | 1 | $53,179 | $-53,179 |
| GRASSO MARC | Chief Financial Officer | 0 | $0 | 4 | $136,917 | $-136,917 |
| Romano Gary | Chief Medical Officer | 0 | $0 | 4 | $141,413 | $-141,413 |
| SCHELLER RICHARD H | director | 0 | $0 | 1 | $228,388 | $-228,388 |
| Kenkare-Mitra Sara | President and Head of R&D | 0 | $0 | 4 | $240,780 | $-240,780 |
| Rosenthal Arnon | Chief Executive Officer | 0 | $0 | 4 | $440,623 | $-440,623 |
About Alector, Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that …
Insider Activity of Alector, Inc.
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.27M worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $19.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
List of Insider Buy and Sell Transactions, Alector, Inc.
| 2025-03-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 40,330 0.0419% | $1.47 | $59,176 | +1.76% | |
| 2025-03-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 29,073 0.0302% | $1.47 | $42,662 | +1.76% | |
| 2025-03-03 | Sale | Romano Gary | Chief Medical Officer | 16,306 0.0169% | $1.47 | $23,927 | +1.76% | |
| 2025-03-03 | Sale | GRASSO MARC | Chief Financial Officer | 18,091 0.0188% | $1.47 | $26,547 | +1.76% | |
| 2024-12-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 52,172 0.0534% | $2.52 | $131,442 | -29.28% | |
| 2024-12-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 26,500 0.0271% | $2.52 | $66,764 | -29.28% | |
| 2024-12-02 | Sale | Romano Gary | Chief Medical Officer | 14,892 0.0152% | $2.52 | $37,519 | -29.28% | |
| 2024-12-02 | Sale | GRASSO MARC | Chief Financial Officer | 16,489 0.0169% | $2.52 | $41,542 | -29.28% | |
| 2024-09-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 26,499 0.0282% | $4.88 | $129,387 | -53.39% | |
| 2024-09-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,926 0.0148% | $4.88 | $67,981 | -53.39% | |
| 2024-09-03 | Sale | Romano Gary | Chief Medical Officer | 8,478 0.009% | $4.88 | $41,385 | -53.39% | |
| 2024-09-03 | Sale | GRASSO MARC | Chief Financial Officer | 7,297 0.0078% | $4.88 | $35,620 | -53.39% | |
| 2024-08-22 | Sale | SCHELLER RICHARD H | director | 44,250 0.0463% | $5.16 | $228,388 | -50.39% | |
| 2024-08-12 | Sale | Yaffe Kristine | director | 5,000 0.0051% | $5.06 | $25,309 | -39.04% | |
| 2024-08-12 | Sale | Hammond Paula | director | 10,500 0.0108% | $5.06 | $53,179 | -39.04% | |
| 2024-06-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 25,135 0.0249% | $4.80 | $120,618 | -9.74% | |
| 2024-06-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,206 0.0131% | $4.80 | $63,373 | -9.74% | |
| 2024-06-03 | Sale | Romano Gary | Chief Medical Officer | 8,040 0.008% | $4.80 | $38,582 | -9.74% | |
| 2024-06-03 | Sale | GRASSO MARC | Chief Financial Officer | 6,920 0.0068% | $4.80 | $33,208 | -9.74% | |
| 2024-03-04 | Sale | Rosenthal Arnon | Chief Executive Officer | 18,837 0.0195% | $6.92 | $130,386 | -29.30% |
Total: 150
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| GORDON CARL L | 10434976 10.5312% | $14.4M | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.9243% | $2.63M | 1 | 17 | +10.01% |
| Wehner David M. | director | 44621 0.045% | $61,576.98 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$30,470,407 | 140 | 20.39% | $134.3M | |
$860,541,348 | 82 | -5.10% | $138.92M | |
$16,245,616 | 40 | 123.58% | $130.89M | |
$909,129 | 37 | 42.19% | $140.26M | |
$64,487,106 | 32 | -22.92% | $141.29M |
ALEC Institutional Investors: Active Positions
| Increased Positions | 79 | +42.93% | 20M | +27.35% |
| Decreased Positions | 75 | -40.76% | 19M | -26.21% |
| New Positions | 31 | New | 17M | New |
| Sold Out Positions | 39 | Sold Out | 11M | Sold Out |
| Total Postitions | 188 | +2.17% | 73M | +1.14% |
ALEC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $21,300.00 | 14.84% | 14.69M | +94,851 | +0.65% | 2024-12-31 |
| Ra Capital Management, L.P. | $14,058.00 | 9.79% | 9.7M | +10M | New | 2024-12-31 |
| Blackrock, Inc. | $13,248.00 | 9.23% | 9.14M | -215,297 | -2.3% | 2024-12-31 |
| Vanguard Group Inc | $8,144.00 | 5.67% | 5.62M | +160,652 | +2.94% | 2024-12-31 |
| Merck & Co., Inc. | $5,141.00 | 3.58% | 3.55M | +4M | New | 2024-12-31 |
| Geode Capital Management, Llc | $2,776.00 | 1.93% | 1.91M | +10,308 | +0.54% | 2024-12-31 |
| State Street Corp | $2,681.00 | 1.87% | 1.85M | -767,514 | -29.33% | 2024-12-31 |
| Jpmorgan Chase & Co | $2,382.00 | 1.66% | 1.64M | -1M | -39.81% | 2024-12-31 |
| Euclidean Capital Llc | $1,896.00 | 1.32% | 1.31M | 0 | 0% | 2024-12-31 |
| Deutsche Bank Ag | $1,604.00 | 1.12% | 1.11M | -48,050 | -4.16% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.